Mineralys Therapeutics CCO Eric Warren sells $209k in stock

Chief Commercial Officer Eric Warren of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) made a notable stock sale on September 21, 2026, selling 7,438 shares of common stock. The transaction, carried out under a pre-approved Rule 10b5-1 plan, yielded a total value of $209,135. Warren executed this sale at a weighted-average price of $28.1172 per share, with individual purchases spanning from $27.94 to $28.21.

The stock's value has since increased to $29.40, and analysts currently view the stock's potential between $30 and $56. Intriguingly, four analysts have recently revised their earnings upward for the upcoming quarter, indicating a positive shift in sentiment despite the insider sale. Prior to this sale, Warren had acquired 7,438 shares through the exercise of stock options, which cost $98,479.

Post-transaction, Warren now holds 38,400 shares directly. These stock options were granted with 25% vesting on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly intervals. Despite the insider sale, Mineralys Therapeutics faces significant financial pressures due to increased spending as the company prepares for the potential launch of its blood pressure drug, lorundrostat.

This has led to a larger-than-expected loss for the second quarter of 2026, with the company reporting an adjusted loss of $2.85 per share, surpassing the expected $2.63 per share loss. Consequently, shares of Mineralys Therapeutics experienced a decline in after-hours trading. The financial results highlight the challenges the company confronts as it invests heavily in its product pipeline.

Analyst firms have yet to update their ratings following this earnings announcement, making the development crucial for investors tracking Mineralys Therapeutics' financial health and strategic direction.